Autopsy report · NCT01200810

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

“Drug was no longer available”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 3 months before it stopped.
• 10 participants enrolled.
• Results were posted on the registry 1 year 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer

Interventions

placebo; gamma-secretase/Notch signalling pathway inhibitor RO4929097; bicalutamide

Participants

10

Sites

1

Countries

United States

Trials that died the same way

• Phase I Study of CS-7017 and Bexarotene
  “Drug no longer available” (95% match in meaning)
• Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
  “Drug was not available.” (88% match in meaning)
• Role of Oxytocin in Telling and Detecting Lies
  “Drug not available” (84% match in meaning)
• BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
  “Drug unavailable” (83% match in meaning)
• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
  “Study drug no longer available” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.